semaglutide aion Your diabetic patient on develops NAION. Do you stop the drug?, The EMA ( European Medicines Agency) says yes — in June 2025 it labeled NAION a very rare side effect of semaglutide and Specialists discuss concerns over impact

Even as millions of Americans have turned to GLP-1 drugs like Ozempic and Mounjaro which suppress appetite, thus leading to weight loss much of the conversation around personal use remains shrouded in secrecy and shame

Numerous clinical trials are exploring the therapeutic roles of glucagon-like peptide (GLP)-1 modulators, insulin-sensitizing thiazolidinediones, and sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with MASLD, which will be discussed in this section

Miras points to data from people taking an earlier GLP-1 formulation known as Saxenda or liraglutide

However, treatment outcomes varied among participants, and medication should always be individualized

The average of these scores was used in statistical analyses

Annual Review of Plant Biology 69, 209236